Recent news on Levalbuterol

Asthma must be treated as serious  -  May 24, 2007
City Vision,Bronchodilators: Short-acting medications include albuterol and levalbuterol, pirbuterol, and terbutaline and are taken as rescue medications.

Sepracor Drops on Reimbursement Concerns  -  May 18, 2007
Forbes,In a recent update of reimbursement codes on the CMS web site, codes distinguishing between Xopenex - referred to by its generic name levalbuterol - and the

Sepracor Announces First Quarter 2007 Results  -  Apr 24, 2007
PharmaLive.com (press release),XOPENEX(R) brand levalbuterol HCl Inhalation Solution -- XOPENEX Inhalation Solution is a short-acting beta-agonist indicated for the treatment or

Brovana Inhalation Solution Now Available by Prescription for ...  -  Apr 11, 2007
PharmaLive.com (press release),Sepracor's sales force has marketed XOPENEX brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or

Sepracor Announces Senior Management Changes  -  Mar 2, 2007
PharmaLive.com (press release),...which has resulted in the success of two major franchises, XOPENEX(R) brand levalbuterol and LUNESTA(R) brand eszopiclone. Over the next six months,

Sepracor Announces Senior Management Changes  -  Mar 1, 2007
Business Wire (press release),...infrastructure of the Company, which has resulted in the success of two major franchises, XOPENEX ® brand levalbuterol and LUNESTA ® brand eszopiclone.

Health : Levalbuterol Is No More Effective Than Older, Cheaper ...  -  Feb 2, 2007
All American Patriots (press release),In 2005, Americans filled more than 2.2 million prescriptions for levalbuterol at a cost of more than $293 million. Marketed by Sepracor Inc., levalbuterol

Levalbuterol Is No More Effective Than Older, Cheaper Asthma Drugs ...  -  Feb 1, 2007
Common Dreams (press release),WASHINGTON - February 1 - Levalbuterol HFA (Xopenex HFA) inhalers are no more effective than older, less expensive drugs used to treat asthma and other

Sepracor Announces Fourth Quarter and Full Year 2006 Results  -  Jan 31, 2007
Business Wire (press release),XOPENEX ® brand levalbuterol HCl Inhalation Solution — XOPENEX Inhalation Solution is a short-acting beta-agonist indicated for the treatment or prevention

Inpatient Management by Hospitalists versus Community Pediatricians  -  Feb 1, 2007
AAP Grand Rounds (subscription),Hospitalists were also more likely to "rarely" or "never" use unproven measures such as levalbuterol for asthma, inhaled and oral steroids for bronchiolitis

Ahead of the Bell: Sepracor  -  Dec 22, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services plans to review its guidelines for when nebulized levalbuterol, including the company's Xopenex inhalable

Sepracor shares up on CMS analysis  -  Dec 21, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services said it will conduct an analysis of nebulized levalbuterol, which includes the company's Xopenex inhalable

Levalbuterol Tartrate Data Presented at American College of ...  -  Nov 28, 2006
DG NewsXopenex HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol or any other component of Xopenex HFA.

Ahead of the Bell: Sepracor  -  Dec 22, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services plans to review its guidelines for when nebulized levalbuterol, including the company's Xopenex inhalable

Sepracor shares up on CMS analysis  -  Dec 21, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services said it will conduct an analysis of nebulized levalbuterol, which includes the company's Xopenex inhalable

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional